Purpose: We compared the accuracy of 18F-Choline-PET/MRI with that of multiparametric MRI (mMRI), 18F-Choline-PET/CT, 18F-Fluoride-PET/CT, and contrast-enhanced CT (CeCT) in detecting relapse in patients with suspected relapse of prostate cancer (PC) after external beam radiotherapy (EBRT).
We assessed the association between standard uptake value (SUV) and apparent diffusion coefficient (ADC).
Methods: We evaluated 21 patients with biochemical relapse after EBRT. Patients underwent 18F-Choline-PET/contrast-enhanced (Ce)CT, 18F-Fluoride-PET/CT, and mMRI. Imaging coregistration of PET and mMRI was performed.
Results: (18)F-Choline-PET/MRI was positive in 18/21 patients, with a detection rate (DR) of 86%. DRs of 18F-Choline-PET/CT, CeCT, and mMRI were 76%, 43%, and 81%, respectively. In terms of DR the only significant difference was between 18F-Choline-PET/MRI and CeCT. On lesion-based analysis, the accuracy of 18F-Choline-PET/MRI, 18F-Choline-PET/CT, CeCT, and mMRI was 99%, 95%, 70%, and 85%, respectively. Accuracy, sensitivity, and NPV of 18F-Choline-PET/MRI were significantly higher than those of both mMRI and CeCT. On whole-body assessment of bone metastases, the sensitivity of 18F-Choline-PET/CT and 18F-Fluoride-PET/CT was significantly higher than that of CeCT. Regarding local and lymph node relapse, we found a significant inverse correlation between ADC and SUV-max.
Conclusion: 18F-Choline-PET/MRI is a promising technique in detecting PC relapse.
Written by:
Piccardo A, Paparo F, Picazzo R, Naseri M, Ricci P, Marziano A, Bacigalupo L, Biscaldi E, Rollandi GA, Grillo-Ruggieri F, Farsad M. Are you the author?
Nuclear Medicine Department, E.O. Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy; Radiology Department, E.O. Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy; Radiotherapy Department, E.O. Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy; Nuclear Medicine Department, Azienda Sanitaria dell'Alto Adige, Via Lorenz Böhler 5, 39100 Bolzano, Italy.
Reference: Biomed Res Int. 2014;2014:103718.
doi: 10.1155/2014/103718
PubMed Abstract
PMID: 24877053
UroToday.com Prostate Cancer Section
